ASTELLAS PHARMA

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 2005-01-01

Employees: -

Market Cap: $22.5B

Website: https://www.astellas.com/

Clinical Trials

A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)

Phase 2

Completed

Conditions: Acute Ischemic Stroke

First Posted Date: 2002-08-20

Last Posted Date: 2006-04-03

Lead Sponsor: Astellas Pharma Inc

Registration Number: NCT00044057

Locations: 🇺🇸
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Maryland Medical System, Baltimore, Maryland, United States
🇧🇪
Dienst Neurologie UZ Gasthuisberg, Leuven, Belgium

and more 114 locations

A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients

Phase 2

Completed

Conditions: Cerebrovascular Accident

First Posted Date: 2002-08-20

Last Posted Date: 2006-04-03

Lead Sponsor: Astellas Pharma Inc

Registration Number: NCT00044070

Locations: 🇺🇸
Holmes Regional Medical Center, Melbourne, Florida, United States
🇺🇸
Johns Hopkins Medical Institute, Baltimore, Maryland, United States
🇺🇸
University of Pittsburgh Medical Center Stroke Institute, Pittsburgh, Pennsylvania, United States

and more 86 locations

CP-461 for the Treatment of Crohn's Disease

Phase 2

Completed

Conditions: Crohn's Disease

First Posted Date: 2002-07-24

Last Posted Date: 2011-10-17

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 30

Registration Number: NCT00042055

Locations: 🇺🇸
Southern Drug Research, Birmingham, Alabama, United States
🇺🇸
Florida Medical Research Institute, PA, Gainesville, Florida, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

and more 7 locations

Study to Assess Efficacy of Tacrolimus + Methotrexate Versus Placebo + Methotrexate in Treatment of Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2002-05-09

Last Posted Date: 2012-03-27

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 210

Registration Number: NCT00036153

Locations: 🇺🇸
Arthritis & Rheumatology Associates of Palm Beach, West Palm Beach, Florida, United States
🇺🇸
Radiant Research - Dallas, Dallas, Texas, United States
🇺🇸
Rheumatology Associates of North Alabama, Huntsville, Alabama, United States

and more 41 locations

Study of FK463 for the Treatment of Invasive Aspergillosis

Phase 2

Completed

Conditions: Aspergillosis

First Posted Date: 2002-05-09

Last Posted Date: 2018-01-10

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 326

Registration Number: NCT00036166

Locations: 🇫🇷
Hopital Henri Mondor, Service d'Hematologie Clinique, Creteil, France
🇫🇷
Hotel Dieu, Service d'Hematologie, Nantes, France
🇫🇷
Hopital Saint Louis, Service D'Hematologie/Greffe de Moelle, Paris, France

and more 20 locations

Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis

Phase 2

Completed

Conditions: Candidiasis

First Posted Date: 2002-05-09

Last Posted Date: 2018-01-10

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 75

Registration Number: NCT00036179

Locations: 🇫🇷
Hopital Henri Mondor, Dervice d'Hematologie Clinique, Creteil, France
🇩🇪
Klinikum der Stadt, Medizinische Klinik A, Ludwigshafen, Germany
🇩🇪
Universitat Wurzburg, Institut fur Molekulare und Infectionsbiologie, Wurzburg, Germany

and more 20 locations

Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea

Phase 2

Completed

Conditions: Diabetes Mellitus

First Posted Date: 2002-05-09

Last Posted Date: 2011-12-09

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 200

Registration Number: NCT00036192

Locations: 🇺🇸
Clireco, Inc., Tamarac, Florida, United States
🇺🇸
Radiant Research - Minneapolis, Edina, Minnesota, United States
🇺🇸
International Institute of Clinical Research, Inc., Ozark, Alabama, United States

and more 30 locations

Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

First Posted Date: 2002-05-09

Last Posted Date: 2011-10-17

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 15

Registration Number: NCT00036257

Locations: 🇺🇸
Albany Regional Cancer Center, Albany, New York, United States
🇺🇸
Cancer Care Northwest, Spokane, Washington, United States
🇺🇸
Tyler Cancer Center, Tyler, Texas, United States

and more 2 locations

Study of CP-461 in Patients With Advanced Renal Cell Cancer

Phase 2

Completed

Conditions: Renal Cell Carcinoma

First Posted Date: 2002-05-08

Last Posted Date: 2011-10-17

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 14

Registration Number: NCT00036036

Locations: 🇺🇸
UCLA Medical Center, Los Angeles, California, United States

Study Using CP-461 to Treat Advanced Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2002-05-08

Last Posted Date: 2011-10-17

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 25

Registration Number: NCT00036075

Locations: 🇺🇸
Columbia Presbyterian Medical Center, New York, New York, United States
🇺🇸
University of Washington, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy